Tumor metastasis is the major cause of deaths in cancer patients and is modulated by intertwined stress-responsive signaling cascades. Here we demonstrate that deletion of stress-responsive apoptosis signal-regulating kinase 1 (Ask1) in platelets results in unstable hemostasis and drastic attenuation of tumor lung metastasis, both of which are attributable to platelet dysfunction. Platelet-specific deletion of Ask1 in mice leads to defects in ADP-dependent platelet aggregation, unstable hemostasis and subsequent attenuation of tumor metastasis. We also revealed that activating phosphorylation of Akt is attenuated in Ask1-deficient platelets, contrary to the previous reports suggesting that Akt is negatively regulated by ASK1. Mechanistically, ASK1-JNK/p38 axis phosphorylates an ADP receptor P2Y 12 at Thr345, which is required for the ADP-dependent sustained Akt activity that is vital to normal platelet functions. Our findings offer insight into positive regulation of Akt signaling through P2Y 12 phosphorylation as well as MAPK signaling in platelets by ASK1 and suggest that ASK1-JNK/p38 axis provides a new therapeutic opportunity for tumor metastasis. Tumor metastasis is the spread of tumor cells from primary tumors to other distant tissues and/or organs and is fatal to cancer patients. Metastatic seeding is a highly inefficient process, thus hindering the investigation of its precise molecular mechanism.
Tumor metastasis is the spread of tumor cells from primary tumors to other distant tissues and/or organs and is fatal to cancer patients. Metastatic seeding is a highly inefficient process, thus hindering the investigation of its precise molecular mechanism. 1 A plethora of evidence suggests that stress-responsive signaling cascades play pivotal roles in the host microenvironment. 1 Mitogen-activated protein kinase (MAPK) pathways are the representative stress-responsive cascades that exert proper cellular responses to divergent environmental stimuli. In response to various stressors, upstream MAPK kinase kinase (MAP3K) phosphorylates and activates MAPK kinase (MAP2K), and MAP2K subsequently activates MAPK. Activated MAPK regulates and induces a wide range of physiological responses. 2, 3 Although MAPKs such as c-Jun NH2-terminal kinase (JNK) and p38 have been revealed to play multifaceted roles in the host environment during tumor progression including tumor metastasis, 4 the upstream regulatory mechanism of these kinases in the context of tumor metastasis was totally unknown. ASK1 is a stress-responsive Ser/Thr MAP3K in the JNK and p38 pathways 5, 6 and accumulating evidence indicates that ASK1 plays important roles in tumorigenesis by regulating apoptosis and inflammation; 7, 8 however, little is known about ASK1's roles in tumor metastasis.
Platelets are anuclear, small cell fragments released from megakaryocytes. Platelets surround tumor cells by adhesion and aggregation in the bloodstream and support tumor metastasis by protecting tumor cells from cell death and immunosurveillance, facilitating their interaction with tumorpromoting leukocytes and assisting their adhesion to vascular endothelial cells. 9 The tumor-promoting effects of platelets have been investigated by gene ablation of relevant molecules such as P-selectin 10 and P2Y 12 (ref. 11) in mice, little reports have referred to the mechanistic insights of these molecules in tumor metastasis.
In this study, we elucidated the impact of ASK1 in the host environment on tumor metastasis and the detailed molecular mechanism of its involvement through regulation of downstream JNK and p38 in platelet functions. Namely, we revealed the regulatory mechanism of P2Y 12 by ASK1-JNK/p38 axis through phosphorylation, thereby linking G protein-coupled receptor (GPCR)-mediated ADP signaling and MAPK pathways in platelets.
Results
Ask1 deficiency in the host environment attenuates tumor lung metastasis. To directly analyze the potential involvement of ASK1 in tumor metastasis, we utilized the experimental lung metastasis model established by intravenous (i.v.) injection of B16F10 melanoma and Lewis lung carcinoma cells constitutively expressing luciferase (B16F10-luc-G5 and 3LL-Luc2 cells, respectively). Fourteen days after i.v. injection of tumor cells, we observed a dramatically reduced number of tumor nodules in the lungs. Consistent with the result, the luciferase activity of the lung lysates of Ask1 − / − mice was significantly reduced compared with control wild-type (Wt) mice (Figures 1a and b) . We also utilized an in vivo bioluminescence imaging to monitor the temporal fate of tumor cells i.v. injected. The signal of 3LL-Luc2 cells was visible in lungs of Wt mice from day 14 after i.v. injection and increased with time (Figures 1c and d) . However, consistent with our macroscopic observations, the signal intensity in the lungs was significantly low in Ask1 − / − mice even at day 26 after injection ( Figure 1c) . Moreover, the survival rate of Ask1 − / − mice was dramatically increased after i.v. injection of 3LL-Luc2 cells (Figure 1e ).
Tumor metastasis consists of multiple steps. Tumor cells that successfully invade from primary lesions are transported to secondary metastatic sites (dissemination process), form emboli within the vasculature and adhere to endothelial cells (colonization process). Only a small fraction of surviving tumor cells can extravasate and form micrometastases, which gradually become macroscopic metastases by tumor cell proliferation. 12 The experimental lung metastasis model can recapitulate the sequential steps including dissemination, colonization, extravasation, proliferation and eventually formation of macroscopic metastasis. We next measured the time-dependent changes of luciferase activity of the lung lysates from 1 h up to 7 days after injection. The luciferase activity dramatically decreased over time until around 24 h after injection and thereafter it starts to increase exponentially in Wt mice (Figure 1f ), reflecting the colonization process followed by proliferation of tumor cells in the course of metastasis. There was minor difference in the dissemination process at 1 h after injection between Wt and Ask1 − / − mice, whereas Ask1 − / − mice showed dramatic attenuation in luciferase activity of the lung lysates as early as 3 days after injection (Figure 1f ), suggesting that ASK1 is involved in the colonization and/or proliferation process (within 3 days after injection) of tumor metastasis.
To examine the potential involvement of ASK1 in tumor cell proliferation during the formation of macroscopic metastases after extravasation, lung carcinoma-derived 3LL-Luc2 cells were orthotopically injected into the lung (Supplementary Figure S1a) . There was no significant difference, however, in tumor cell growth between Wt and Ask1 − / − mice. We also observed no difference in the ectopic growth of 3LL-Luc2 cells subcutaneously injected into the dorsal skin of Wt and Ask1 − / − mice (Supplementary Figure S1b) . Thus, we hypothesized that Ask1 deficiency may affect the colonization stage rather than the proliferation stage after formation of micrometastases.
ASK1 in bone marrow-derived cells facilitates tumor lung metastasis. We next generated bone marrow chimeric mice to identify the cell types in which ASK1 regulates tumor metastasis. The luciferase activity in the lungs was reduced in Wt mice whose bone marrow was replaced with Ask1 − / − mice whose bone marrow was replaced with Wt mice (Wt-Ask1 − / − mice) compared with the control (Wt-Wt) mice (Figure 2a) . These results suggest that ASK1 contributes to metastasis in both bone marrow-derived cells and recipient cells. Among bone marrow-derived cells, critical roles of myeloblasts such as granulocytes, monocytes and macrophages in tumor metastasis have been suggested. 13 Hence, we utilized myeloblastspecific Ask1-deficient mice (Lysm-cre; Ask1 F/F mice). Lysmcre; Ask1 F/F mice exhibited almost complete deletion of Ask1 in peritoneal macrophages (Figure 2b ) but not in platelets (Figure 2c ) 14 or whole lungs (Figure 2d) . Surprisingly, the luciferase activities of the lung lysates from Lysm-cre; Ask1 F/F mice and Ask1 F/F mice were comparable at 14 days after injection of B16F10-luc-G5 cells (Figure 2e ) and 3LL-Luc2 cells (Figure 2f ), suggesting that ASK1 in bone marrowderived cells other than myeloblasts regulates tumor lung metastasis.
Platelet-intrinsic Ask1 deficiency leads to unstable hemostasis. Platelets are non-myeloblastic bone marrowderived cells and play critical roles in hematogenous tumor metastasis. The tumor metastasis-promoting effects of platelets are inhibited by the decline in number or function. 9 It was recently reported that ASK1 maintains hemostasis through platelet granule secretion by using conventional Ask1 − / − mice. 15 Similar to the report, Ask1 − / − mice showed no differences in the number of platelets and hematological parameters compared with Wt mice (Supplementary Table  S1 ) as well as surface expression of major platelet receptors (Supplementary Figure S2a) . In addition, the bleeding time in tail bleeding assays (Supplementary Figure S2b) and the occlusion time in FeCl 3 -induced thrombosis assays (Supplementary Figure S2c ) were also confirmed to be significantly prolonged in ASK1 − / − mice. However, these phenotypes of Ask1 − / − mice in hemostasis cannot exclude the potential involvement of other cell types (such as endothelial cells) than platelets in hemostasis. To examine if Ask1 deficiency in platelets contributes to unstable hemostasis, we newly generated platelet-specific Ask1-deficient mice (Pf4-cre; Ask1 F/F mice). 16 Pf4-cre; Ask1 F/F mice exhibited almost complete deletion of ASK1 in platelets (Figure 3a) but not in whole lungs (Figure 3b ). The hematological parameters and surface expression of major platelet receptors of Pf4-cre; Ask1 F/F mice were indistinguishable from Ask1 F/F mice (Supplementary Table S1 and Supplementary Figure S3) . Moreover, both the bleeding time in tail bleeding assays (Figure 3c ) and the occlusion time in FeCl 3 -induced thrombosis assays ( Figure 3d ) were significantly prolonged in Pf4-cre; Ask1 F/F mice. These data strongly suggest that platelet-intrinsic ASK1 is critical to unstable hemostasis phenotype observed in conventional Ask1 − / − mice.
Activating phoshorylation of Akt, JNK and p38 is reduced in Ask1-deficient platelets. JNK and p38 are downstream effectors of ASK1. 5, 6 Also, they are known to have critical roles in hemostasis and thrombosis; 17, 18 hence, we speculated that ASK1 functions as an upstream regulator of JNK and p38 in platelets. As expected, in platelets of Ask1 − / − and Pf4-cre; Ask1 F/F mice, the activating phosphorylation of JNK and p38 were dramatically attenuated (Figures 3e and f) . Interestingly, the activating phosphorylation of Akt (at Thr308 and Ser473), which is required for platelet aggregation and hemostasis, 19 was strongly reduced in platelets of Ask1 − / − and Pf4-cre; Ask1 F/F mice (Figures 3e and f). ASK1 and Akt were reported to mutually inhibit their activities by phosphorylation. 20, 21 Thus, our data contrast to the previous reports in that ASK1 positively, rather than negatively, regulates Akt activity, suggesting the distinctive regulatory mechanism of Akt phosphorylation by ASK1 in platelets. In sum, these results suggest that ASK1 may be involved in normal platelet functions through activations of JNK, p38 and Akt.
Ask1-deficient platelets are refractory to ADP-dependent stimulations. To investigate what kind of signals ASK1 regulates in the context of platelet aggregation, we next studied in vitro platelet aggregation induced by various agonists. When platelets of Ask1 − / − mice were exposed to collagen, PAR-4 activating peptide and rhodocytin, the ligand of CLEC-2, platelet aggregation was significantly reduced compared with Wt mice (Supplementary Figures S4a-c) . 15 By contrast, thrombin-induced platelet aggregation was not abrogated in Ask1 − / − mice (Supplementary Figure S4d) . Platelet aggregation induced by collagen or rhodocytin is largely dependent on ADP as a secondary mediator. [22] [23] [24] Moreover, PAR-4 activating peptide but not thrombin depends on ADP receptor P2Y 12 to activate integrin αIIbβ3 and subsequent fibrinogen binding, and eventually induces platelet aggregation. 25 Considering these reports, our data suggest that ASK1 contributes to ADP-dependent platelet activation. As expected, platelet aggregation induced by ADP was dramatically abrogated in Ask1 − / − mice (Supplementary Figure S4e) . Similar to Ask1 − / − mice, platelet aggregation of Pf4-cre; Ask1 F/F mice was attenuated under stimulation with collagen ( Figure 3g ) and ADP (Figure 3h ) but not with thrombin ( Figure 3i ). In summary, Ask1 deficiency attenuates ADP-dependent aggregation in platelets.
ASK1 regulates phosphorylation of ADP receptor, P2Y 12 . ADP activates two purinergic GPCRs, P2Y 1 and P2Y 12 , to initiate platelet aggregation. P2Y 1 and P2Y 12 associate with G q and G i , respectively, for full platelet activation. Binding of ADP to P2Y 1 induces elevation of intracellular calcium and activation of Rho kinases, whereas ADP binding to P2Y 12 activates the PI3K-Akt pathway and inhibits adenylyl cyclase (AC), etc. 26 As mentioned above, the activating phosphorylation of Akt was attenuated in platelets of Ask1 − / − mice as well as of Pf4-cre; Ask1 F/F mice (Figures 3e and f) . Considering that a large proportion of Akt activation by ADP is attributable to P2Y 12 in platelets, 27 we hypothesized that ASK1 may modulate ADP signaling through the P2Y 12 receptor.
Platelet P2Y 12 protein levels were comparable in Ask1
F/F and control (Wt and Ask1 F/F ) mice (Figure 4a) . Interestingly, however, the bands for P2Y 12 from Ask1 − / − and Pf4-cre; Ask1 F/F mice migrated faster than the band from control mice in SDS-PAGE (Figure 4a) . Thus, we assumed that aberrant post-translational modification of P2Y 12 in Ask1-deficient platelets causes platelet dysfunction. Previous reports indicate that P2Y 12 is subject to phosphorylation and glycosylation. 28 When platelet lysates were treated with the protein phosphatase λPPase, the band for P2Y 12 from platelets of Wt mice was downshifted to the same position of that from Ask1 − / − mice (Figure 4b ), suggesting that ASK1 modulates P2Y 12 phosphorylation.
Phosphorylation of mP2Y 12 at Thr345 by ASK1-JNK/p38 axis sustains Akt signaling induced by ADP stimulation. Next, we attempted to identify the phosphorylation site(s) of P2Y 12 affected by ASK1. Considering that JNK and p38 (downstream of ASK1) regulate platelet functions and hemostasis, 17, 18 we assumed that these kinases might be responsible for the direct phosphorylation. We searched for consensus phosphorylation sites (Ser-Pro or Thr-Pro) targeted by JNK and p38 in P2Y 12 . Only one Thr-Pro (TP) site at the C-terminus was conserved between human and mouse P2Y 12 (mP2Y 12 ; Figure 4c ). To determine if ASK1 regulates phosphorylation of this TP site in mouse platelets, we generated an anti-phospho-P2Y 12 antibody (p-P2Y 12 Thr 345 ) as described in the Materials/Subjects and Methods (Thr 340 in human). The signal of the p-P2Y 12 Thr 345 antibody was specifically detected in CHO cells exogenously expressing mP2Y 12 -WT but not phosphorylation-defective mP2Y 12 -T345A or control lacZ, and the signal was completely abolished by λPPase treatment (Figure 4d ). We thus investigated the phosphorylation status of endogenous P2Y 12 at Thr345 in platelets. Strikingly, Thr345 phosphorylation of P2Y 12 was strongly attenuated in Ask1-deficient platelets, suggesting that ASK1 is responsible for this phosphorylation in platelets (Figure 4e ).
We next evaluated the impact of the defects in P2Y 12 phosphorylation on the downstream signaling. ADP-dependent activation of Akt monitored by phosphorylation of Akt at Ser473 was clearly increased when CHO cells exogenously express mP2Y 12 -WT but not control lacZ (Figure 5a ), confirming that exogenously expressed mP2Y 12 can activate Akt in response to ADP stimulation. ADP stimulation led to sustained Akt activity up to 120 min in CHO cells expressing mP2Y 12 -WT, while it was attenuated from 60 min after stimulation in mP2Y 12 -T345A expressing cells (Figure 5b ). A previous study identified a patient with a substitution from Pro to Ala in the corresponding TP site (P341A) of human P2Y 12 and suggested that this mutation attenuates receptor internalization and resensitization, resulting in bleeding phenotype. 29 Defects in resensitization of GPCRs impair sustained downstream signaling in general. 30 Consistently, Akt activity in CHO cells exogenously expressing mP2Y 12 -P346A mutant (P341A in human) was clearly attenuated from 40 to 60 min after ADP stimulation (Figure 5b) , which is similar to -T345A mutant. Moreover, pretreatment with JNK and p38 inhibitors additively reduced ADP-dependent Akt activity from 40 to 60 min with little effect at 5 min after stimulation (Figure 5c ), consistent with the result of mP2Y 12 -T345A mutant. These results suggest that JNK and p38 are responsible kinases, which phosphorylate mP2Y 12 at Thr345 and enable sustained Akt activation through mP2Y 12 . Collectively, our data suggest that platelet-intrinsic ASK1-JNK/p38 axis maintains stable hemostasis and proper ADP signaling in platelets through phosphorylation of mP2Y 12 at Thr345.
Ask1 deficiency in platelets attenuates tumor lung metastasis. Hemostasis and ADP-dependent platelet aggregation were attenuated in P2y 12 − / − mice 31 and conversely enhanced in transgenic mice expressing the constitutively active form of P2y 12 (cP2y 12 -Tg mice), 32 indicative of essential roles of P2Y 12 in platelet functions. Moreover, deletion of P2y 12 in mice 11 or treatment of P2Y 12-specific inhibitors such as clopidogrel and ticagrelor to mice 33 attenuated tumor metastatic burden, suggesting the pivotal roles of P2Y 12 in tumor metastasis. Thus, we examined whether Ask1 deficiency solely in platelets attenuates tumor lung metastasis, although ASK1 contributes to metastasis in both bone marrow-derived cells and recipient cells (Figure 2a ). Luciferase activity at 14 days after i.v. injection of B16F10-luc-G5 cells was significantly reduced in lung lysates from Pf4-cre; Ask1 F/F compared with Ask1 F/F mice (Figure 5d ). Hence, Ask1 deficiency in platelets attenuates platelet functions, leading to unstable hemostasis and reduced tumor metastatic burden. Collectively, our data suggest that plateletintrinsic ASK1-JNK/p38 axis may validate proper ADP signaling in platelets through phosphorylation of mP2Y 12 at Thr345, which enhances thrombosis/hemostasis and hematogenous tumor metastasis (Figure 5e ).
Discussion
This study elucidated for the first time the regulatory mechanism by which an MAP3K, the most upstream components of the MAPK pathway, contributes to tumor lung metastasis and platelet functions in vitro and in vivo. A part of the present study on thrombus formation using the conventional Ask1 − / − mice is consistent with a recent report from other laboratory. 15 Our study further elucidated the regulatory mechanism of tumor metastasis by ASK1 in platelets utilizing conventional and platelet-specific Ask1-deficient mice. Furthermore, we revealed that not only JNK/p38 but also Akt activity was strongly reduced in Ask1-deficient platelets (Figures 3e  and f) and that P2Y 12 is a direct substrate downstream of ASK1-JNK/p38 axis, which regulates sustained Akt activity (Figures 5b and c) .
In this study, however, we cannot exclude other mechanisms than phosphorylation of P2Y 12 , which are responsible for attenuation of tumor metastasis by platelet-intrinsic Ask1 deficiency. It was recently reported that ASK1 contributes to granule secretion and production of thromboxane A 2 from platelets under various conditions including ADP stimulation. 15 Moreover, a variety of factors secreted from granules facilitate tumor metastasis via platelet activation and aggregation, and interaction between platelets and tumor cells. 9 Therefore, our proposed regulatory mechanism of P2Y 12 -mediated ADP signaling by ASK1 might be independent or upstream as well as downstream of secreted factors from platelets.
As mentioned previously, ADP activates two purinergic GPCRs, P2Y 1 and P2Y 12 , to initiate platelet aggregation. Naik et al. also demonstrated that the extent of intracellular calcium influx within platelets stimulated with ADP is comparable between Wt and Ask1 − / − mice. Considering that P2Y 1 is responsible for intracellular calcium influx under ADP stimulation, 26 it seems unlikely that ASK1 modulates ADP signaling in platelets and thereby platelet-dependent tumor metastasis through P2Y 1 .
The importance of N-type glycosylation of P2Y 12 is reported for its signaling; 34 however, the impact of phosphorylation of P2Y 12 on its function and subsequent hemostasis and tumor metastasis has been largely unknown. We newly identified Thr345 of mP2Y 12 , which is subject to phosphorylation by the ASK1-JNK/p38 axis, and revealed that this phosphorylation is important for ADP signaling. Although lines of evidence suggest that GPCRs modulate MAPK signaling as downstream effectors, 30 the present study is the first to report that the JNK/p38 pathway directly phosphorylates GPCR and thereby regulate its function. As mentioned, engagement of ADP to P2Y 12 leads to inhibition of AC as well as activation of the PI3K-Akt pathway. Gα i and Gβ/γ coupled to P2Y 12 are responsible for the former and the latter signaling, respectively. 26 Our data suggested that ASK1-mediated phosphorylation of P2Y 12 affects PI3K-Akt pathway; however, it is also considerable not only Gβ/γ-but also Gα i -mediated signaling to AC may be affected by phosphorylation of P2Y 12 . Further study is needed to investigate the effects of ASK1 and of phosphorylation at Thr345 of P2Y 12 on the activity of AC.
Of note, P341A mutation of human P2Y 12 was found in a patient with bleeding phenotype and suggested to attenuate receptor internalization and resensitization. 29 In general, defects in resensitization of GPCRs impair sustained downstream signaling. 30 It is thus plausible that ADP-dependent sustained Akt activity as a downstream of P2Y 12 may be affected in P341A (P346A in mice) mutant. We revealed that sustained activity of Akt was abolished not only in CHO cells exogenously expressing mP2Y 12 -P346A mutant but also in those expressing mP2Y 12 -T345A mutant (Figure 5b) . Moreover, CHO cells exogenously expressing mP2Y 12 -WT treated with inhibitors of JNK and/or p38 also had defects in sustained activity of Akt (Figure 5c ). These data suggest that defects in phosphorylation of mP2Y 12 at Thr345 by ASK1-JNK/p38 axis may attenuate downstream signaling via recycling and/or resensitization of P2Y 12 in the similar manner as P346A mutant. Previous study suggested that activated P2Y 12 by ADP is subject to phosphorylation by GPCR kinase (GRK) 2 and GRK6, resulting in desensitization; 35 however, the phosphorylation sites of P2Y 12 by these kinases and the precise mechanism of the phosphorylation have not been identified. It is possible that GRKs also regulate the phosphorylation of mP2Y 12 at Thr345 as ASK1-JNK/p38 axis. Thus, further study is needed to investigate how and whether ASK1-JNK/p38 axis and GRKs cooperate to regulate P2Y 12 function.
We have revealed that Ask1 deficiency attenuates tumor metastasis, resulting in the drastic extension of the lifespan. Importantly, ASK1 not only in bone marrow-derived cells but also in recipient cells in the setting of bone marrow chimeric mice is required for tumor metastasis (Figure 2a ). These data suggest that ASK1 not only in platelets but in other cell types, such as fibroblasts and/or endothelial cells, may also promote tumor metastasis. Further study is needed to reveal the function of ASK1 in those cell types in the context of tumor metastasis. Moreover, not only the multifaceted functions of ASK1 in multiple cell types but also the quantitative fluctuation of ASK1 may be involved in the progression of tumor metastasis. It is possible, for example, that upregulated ASK1 in platelets in the presence of incipient tumor metastasis might further facilitate P2Y 12 and platelet functions to aggravate tumor metastasis.
In conclusion, our study provides a molecular insight into regulation of tumor metastasis by platelet-intrinsic ASK1 and may implicate a therapeutic potential of ASK1 against tumor metastasis.
Materials/Subjects and Methods
Mice. The generation of Ask1 − / − mice has been described previously. 6 Mice homozygous for the Ask1 floxed allele (Ask1 F/F ) on a C57BL/6 background were generated as previously described. 36, 37 Pf4-cre mice were purchased at the Jackson Laboratory (Sacramento, CA, USA). Lysm-cre mice were obtained from RIKEN (Tsukuba, Japan). The mice were housed in a specific pathogen-free facility and were used for experiments at 8-to 16-week-old. Age-matched female mice were used for all experiments. The experimental protocol was approved by the animal ethics committee of The University of Tokyo (Tokyo, Japan).
Bone marrow chimeras. Chimeras were generated by reconstituting irradiated (10 Gy of γ-radiation) 8-week-old Wt and Ask1 − / − mice with bone marrow cells (1.7 × 10 7 cells, i.v.) from sex-matched Wt or Ask1 − / − donor mice. Eight weeks later, tumor implantation was carried out as described below. Lung dissection was performed 7 days after tumor cell injection.
Cell culture. Luciferase-expressing Lewis lung carcinoma 3LL (3LL-Luc2) cell line was kindly provided by Dr. Yoshihiro Hayakawa (University of Toyama). Luciferase-expressing melanoma B16F10-luc-G5 cells (Xenogen Corp., Alameda, CA, USA) were maintained in DMEM-high glucose medium (Sigma, St. Louis, MO, USA) supplemented with 100 units/ml penicillin G, 10% fetal bovine serum (FBS) and 0.25 mg/ml zeocin. 3LL-Luc2 cells were maintained in RPMI-1640 medium (Sigma) supplemented with 100 units/ml penicillin G and 10% FBS. Chinese Hamster Ovary (CHO) cells were maintained in Ham's F-12 medium (Wako Chemicals, Osaka, Japan) supplemented with 100 units/ml penicillin G and 10% FBS. Cells were cultured in a 5% CO 2 atmosphere at 37°C. The absence of mycoplasma was confirmed.
Antibodies and reagents. The polyclonal antibody to phospho-ASK1 (pT845) was described previously, 38 which was used as P-ASK antibody. The antibody to ASK1 (EP553Y) was purchased from Abcam (Cambridge, UK) and the antibody to P2Y 12 (APR-012) was purchased from Alomone Labs (Jerusalem, Israel). Phospho-specific antibodies to JNK (P-JNK: Thr 183 /Tyr 185 ), p38 MAPK (P-p38: Thr 180 /Tyr 182 ), Akt (P-Akt Ser 473 and P-Akt Thr 308 ) and the antibody to p38 (p38 L53F8) and Akt (pan) (11E7) were purchased from Cell Signaling (Danvers, MA, USA). The antibody to JNK (JNK-FL) and Actin (AC-40) were purchased from Santa Cruz (Dallas, TX, USA). A rabbit polyclonal antibody specific for phospho-P2Y 12 (P-P2Y 12 Thr 345 ) was raised against the phosphopeptide GEPSEE(pT)PM of mouse P2Y 12 as described previously. 39 ADP was purchased from Wako. p38 inhibitor SB203580 and JNK inhibitor SP600125 were purchased from Merck Millipore (Billerica, MA, USA). Cells were pretreated with SB203580 and/ or SP600125 at 10 μM for 30 min. Mouse P2Y 12 (mP2Y 12 )-WT and -T345A constructs were generated by PCR of mouse blood cDNA template and cloned into pAd/CMV/V5 to generate adenoviruses encoding the above-mentioned constructs or control lacZ according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Luciferase activity assay. Mouse lungs were homogenized in Luciferase Culture Lysis 5 × Reagent diluted with distilled water (Promega, Madison, WI, USA). The lysates were cleared by centrifugation and analyzed using the Luciferase Assay System (Promega).
In vivo bioluminescence imaging. Mice were epilated, anesthetized with avertin and administered D-luciferin potassium (Wako Chemicals) intraperitoneally to monitor luciferase activity in vivo with NightOWL II LB983 (Berthold Technologies, Bad Wildbad, Germany). The luciferase activity from the ROI was measured in units of photons per second.
Tail bleeding assay. Mice were anesthetized with pentobarbital (50 mg/kg, intraperitoneally) and placed in a cloth holder warmed to 37°C. The mouse tail was transected 5 mm from the tip, immersed in PBS at 37°C and the bleeding time was determined when the bleeding stopped for more than 30 s. Tail bleeding assay was ceased at 600 s if the bleeding did not stop.
FeCl 3 -induced thrombosis model. Mice were anesthetized and the right femoral artery was exposed and 1 mm 2 filter paper immersed in 10% FeCl 3 was applied onto it. The occlusion time was determined if the flow fell below 10 ml/min per 100 g weight for 1 min.
Measurement of hematological parameters. Mouse blood was collected from the tips of mouse tail and diluted with 25 mM EDTA/PBS. Hematological parameters were analyzed by XE-2100 (Sysmex, Kobe, Japan).
Isolation of platelets for platelet aggregation. Whole blood was collected into tubes with citrate anticoagulant from anesthetized mice by inferior vena cava puncture with a 23-gauge needle. Supernatants were collected after centrifuging blood (100 × g for 10 min twice) for preparation of platelet-rich plasma (PRP). Platelets were precipitated by centrifugation of PRP (2300 r.p.m. for 10 min) with 10 nM prostacyclin (Cayman Chemical, Ann Arbor, MI, USA). Precipitated platelets were suspended in Calcium-Free Tyrode buffer (CFT) to adjust platelet population (platelet suspension). Aggregation of platelet suspension was analyzed with MCM HEMA TRACER 712 (MC MEDICAL, Tokyo, Japan) for 10 min. Platelet aggregation was induced with collagen (1 μg/μl; Takeda, Osaka, Japan), PAR-4 (50 μM; Sigma), rhodocytin (1 nM, purified as previously described), 40 ADP (10 μM; MC Medical) and thrombin (0.025 U/ml; Haematologic Technologies, Essex Junction, VT, USA).
Surface expression of platelet receptors by flow cytometry. Samples of PRP were incubated with the following antibodies and analyzed by FACS Accuri C6 (BD Biosciences): FITC-labeled anti-mouse CD41 (clone MWReg30; BD Biosciences), FITC-labeled anti-CD61 (clone Luc.H11; Haematologic Technologies),
